

4Q FY21 Investor Briefing



Disclaimer

This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below.

This document is not a prospectus, product disclosure statement or other offer document under Australian law or under any other law and has not been filed, registered or approved by regulatory authorities in any jurisdiction. This document does not constitute an offer, invitation, solicitation or recommendation to acquire any shares in the Company. The information contained in this document is not intended to be relied upon as advice or a recommendation to investors and does not take into account the investment objectives, financial situation, taxation situation or needs of any particular investor. An investor must not act on the basis of any matter contained in this document but must make its own assessment of the Company and conduct its own investigations and analysis. Investors should assess their own individual financial circumstances and consider talking to a financial adviser, professional adviser or consultant before making any investment decision.

Neither the Company nor any of its directors, officers, employees, contractors, agents or advisers (Limited Party) makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this document. No Limited Party represents or warrants that this document is complete or that it contains all information about the Company that a prospective investor may require in evaluating a possible investment in the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault, negligence or omission on the part of any person, for any loss or damage arising from the use of, or reliance on, information contained in this document or otherwise arising in connection with it.

Certain statements in this document constitute forward looking statements and comments about future events, including with respect to the financial condition, results of operations and business of the Company and certain plans and objectives of the management of the Company. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, you are cautioned to not place undue reliance on any forward looking statement. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. No Limited Party or any other person makes any representation as to the accuracy or likelihood of the fulfilment of any forward-looking statements, or gives any assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statements in this document will occur.



Table of Contents

Section	Topic	Page
1	4Q Results Executive Summary	1
2	Company Information	2
3	Cash Flow Summary	3
4	Product Development	4
5	Market Expansion	5
6	Summary	6



1 4Q Results Executive Summary

Cash Receipts

\$4.4M

▼ 12.5% from 3Q FY21

Cash Flow from Operations

\$0.6M

△ 158.2% from 3Q FY21

Cash & Cash Equivalents

\$8.9M

△ 6.8% from 3Q FY21

Total Stock Keeping Units

39

▲ 7% from 3Q FY21

Distribution Points

980+

▲ 40 from 3Q FY21

Near-term Outlook

Growth

driven by jurisdiction & channel expansion

2 Company Information

Company Background

Operation:



104 Derby Street, Silverwater, NSW 2128, Australia

Brands & Products:





EZZ

Exclusive wholesale distributor of skin care products under the EAORON brand to selected channels

Producer of consumer health products under the brand of EZZ

Top 5 Shareholders

Macquarie Holdings Pty Ltd	40.5%
JNJ Mok Pty Ltd	27.0%
Yong Cao	4.2%
Haitao Zheng	1.1%
Jing Chen	1.1%

Company History

July 2018

Started operations as a wholesale distributor of the EAORON branded skincare products

July 2020

March 2021 Listed on the ASX

Became an exclusive distributor of EAORON branded products in Australia and New Zealand

December 2019


Commenced producing and selling EZZ branded health supplements

March 2020

Generated early stage revenue from selling the EZZ branded products

July 2020

Started operating EZZ's store on Tmall Global




Share Information

ASX Code:	EZZ
Close (30 June 2021):	\$0.445
Shares on Issue:	42.0M
Market Cap. (30 June 2021) :	\$18.7M
52 week price range:	\$0.38-\$1.43



3 Cash Flow Summary





4 Product Development

Previous Period

Current Period



NMN 150,000 mcg



JTN



Magic Gummy

A health food containing ingredients that help to support collagen production and skin health




A supplement listed on the Australian Register of Therapeutic Goods that helps to maintain energy levels, reduce free radicals, and support blood circulation.



Coffee Jelly

A health food which contains ingredients that stimulate bowel movements

5 Market Expansion



EZZ

6 Summary

- EZZ Life Science Holdings Limited (EZZ) is a newly listed beauty and health company expanding into global markets
- Solid cash position of \$8.9m
- Cash receipts of \$4.4m, with operating cash inflows of \$0.6m
- Recently expanded distribution channels via Costco and MINISO
- Accelerating product development three new products added to health supplements portfolio
- Advancing negotiations with new distributors to stock EZZ branded products
- Experienced Board and Management team to drive growth for EZZ in FY22

EZZ LIFE SCIENCE HOLDINGS LIMITED [ASX: EZZ]

For further information in relation to EZZ's June Quarter results, please view commentary from our CEO, Fernando Rodriguez here: https://ezzlife.com.au/presentations/

For further information, please contact:

Fernando Rodriguez, CEO ir@ezzlife.com.au

